HLA matching in the development of leading-edge allogeneic therapeutics and cellular therapies—and hematopoietic stem cell transplantation (HSCT)—isn’t only about finding the best matches. It’s also about avoiding mismatches that could result in less optimal patient outcomes.
During this on-demand webinar, you’ll hear from industry experts about research identifying HLA-B mismatches that are most optimal. You’ll also learn which cause negative effects. The panel also discusses an automated HLA-B leader matching assessment tool. This tool can be used to help avoid mismatching for HLA-B alleles associated with higher risks for future patients.
Understanding donor HLA characteristics and their impact on the final therapy can ultimately improve allogeneic cell therapy outcomes.
Get insights into:
- The science of the HLA-B leader peptide and its functional role in cell therapy outcomes
- How the HLA-B-leader tool—initially created to support NDMP initiatives and research on optimizing HSCT success using mismatched donors—can be used by the cell therapy field in donor source selection
- The impact these tools and research will have on improving patient outcomes in HSCT and emerging cell and gene therapies
Speakers
- Effie Wang Petersdorf, MD, Professor, Clinical Research Division & Madeline Dabney Adams Endowed Chair in AML Research Fred Hutchinson Cancer Research Center
- Ray Sajulga, Jr., Bioinformatics Scientist, NMDP
- Martin Maiers, MS, Vice President of Innovation, NMDP
- Kim Wadsworth, Senior Immunogenetic Specialist, NMDP
View Webinar
